ARS Pharmaceuticals Inc (SPRY) News

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a...

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

Six posters and oral presentations to be presented, including efficacy data for neffy from two distinct clinical studies in oral food challenge...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data...

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific...

ARS Pharmaceuticals to Meet With FDA on Neffy Rejection

By Colin Kellaher ARS Pharmaceuticals will meet later this month with the U.S. Food and Drug Administration to discuss the agency's rejection...

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering...

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

neffy resulted in robust responses on pharmacodynamic (PD) surrogates of efficacy observed even at 1 minute after dosing, and which were...

Form 8-K - Current report

ARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy Setback

By Colin Kellaher ARS Pharmaceuticals shares lost more than half of their value and hit an all-time low on Wednesday after the U.S. Food and Drug...

ARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray

By Colin Kellaher ARS Pharmaceuticals shares plunged in premarket trading Wednesday after the U.S. Food and Drug Administration rejected its...